AU2001296545A1 - Methods of therapy for b-cell malignancies - Google Patents

Methods of therapy for b-cell malignancies

Info

Publication number
AU2001296545A1
AU2001296545A1 AU2001296545A AU9654501A AU2001296545A1 AU 2001296545 A1 AU2001296545 A1 AU 2001296545A1 AU 2001296545 A AU2001296545 A AU 2001296545A AU 9654501 A AU9654501 A AU 9654501A AU 2001296545 A1 AU2001296545 A1 AU 2001296545A1
Authority
AU
Australia
Prior art keywords
antigen
antibody
cell
methods
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296545A
Other languages
English (en)
Inventor
Keting Chu
Lorianne Masuoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001296545A1 publication Critical patent/AU2001296545A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001296545A 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies Abandoned AU2001296545A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23755600P 2000-10-02 2000-10-02
US60237556 2000-10-02
US60/237,556 2000-10-02
PCT/US2001/030961 WO2002028480A2 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies

Publications (1)

Publication Number Publication Date
AU2001296545A1 true AU2001296545A1 (en) 2002-04-15

Family

ID=22894238

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2001296545A Abandoned AU2001296545A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies
AU2001296547A Abandoned AU2001296547A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2001296507A Abandoned AU2001296507A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
AU2002211366A Abandoned AU2002211366A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2001296547A Abandoned AU2001296547A1 (en) 2000-10-02 2001-10-02 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2001296507A Abandoned AU2001296507A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies
AU2002211366A Abandoned AU2002211366A1 (en) 2000-10-02 2001-10-02 Human anti-cd40 antibodies

Country Status (10)

Country Link
US (5) US7288252B2 (https=)
EP (3) EP1322383B9 (https=)
JP (6) JP4271440B2 (https=)
AT (3) ATE327004T1 (https=)
AU (4) AU2001296545A1 (https=)
CA (2) CA2424749A1 (https=)
DE (2) DE60119945T2 (https=)
ES (1) ES2357051T3 (https=)
PT (1) PT1326896E (https=)
WO (4) WO2002028904A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
EP1322383B9 (en) * 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
PL1680141T3 (pl) * 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
ATE447412T1 (de) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
SI1682177T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
KR101128777B1 (ko) 2003-11-04 2012-04-13 조마 테크놀로지 리미티드 다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
WO2005044307A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP1879923B1 (en) 2005-04-09 2015-05-27 Fusion Antibodies Limited Cathepsin s antibody
JP5421590B2 (ja) * 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
ES2400660T3 (es) * 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
MX2010005099A (es) * 2007-11-09 2010-05-27 Novartis Ag Usos de anticuerpos anti-cd40.
CA2712989C (en) 2008-01-23 2015-10-27 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
CN102770457A (zh) 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
CA2831294A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
HUE038848T2 (hu) 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
ES2716823T3 (es) 2011-11-17 2019-06-17 Jung Gundram Anticuerpos biespecíficos para uso médico
JP2016011258A (ja) * 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
CA2891764A1 (en) 2012-11-19 2014-05-22 Baliopharm Ag Recombinant bispecific antibody binding to cd20 and cd95
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
EP3113796A1 (en) 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
BR112017008959A2 (pt) 2014-10-29 2018-01-16 Seattle Genetics, Inc. método para tratamento de uma doença.
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
BR112018006251A2 (pt) 2015-09-30 2018-10-16 Janssen Biotech Inc anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2018278051A1 (en) 2017-06-01 2020-01-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN108503708B (zh) * 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 抗人cd47抗体及其用途
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
BR112021009835A2 (pt) 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
US20240254248A1 (en) 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
NL2022494B1 (en) * 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
IL305681A (en) 2021-03-09 2023-11-01 Genmab As Multispecific binding agents against cd40 and cd137 in therapy
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
JP2024518456A (ja) 2021-05-07 2024-05-01 レドキック、 オーワイ 貨物輸送オペレーションのリスク確率評価及びその使用の方法
JP2024523514A (ja) * 2021-06-28 2024-06-28 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ４０抗体、その抗原結合断片及び医薬用途
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CN120463762A (zh) 2021-08-26 2025-08-12 映恩生物科技(上海)有限公司 一种甾体化合物及其缀合物
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
US20250249278A1 (en) 2022-04-14 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US59427A (en) * 1866-11-06 Improvement in fences
US142358A (en) * 1873-09-02 Improvement in the purification of illuminating-gas
US4355023A (en) * 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4689299A (en) * 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ212051A (en) * 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5068223A (en) * 1985-09-09 1991-11-26 Board Of Regents, University Of Texas System Hydrophobic peptide esters and amides
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US4923872A (en) * 1986-08-26 1990-05-08 Warner-Lambert Co. Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
ES2051726T3 (es) * 1987-01-17 1994-07-01 Asta Medica Ag Procedimiento para preparar productos inyectables que contienen azelastin y teofilina o azelastin y beta-mimeticos.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0434879A1 (en) 1989-12-14 1991-07-03 Schering-Plough Method of making factor dependent human B cell lines
EP0537293A4 (en) 1990-07-02 1993-09-08 Bristol-Myers Company Ligand for cd28 receptor on b cells and methods
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
IL104684A0 (en) 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU4554493A (en) 1992-07-07 1994-01-31 Eleanor N. Fish Interferon receptor binding peptides
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DK0945465T3 (da) 1992-07-09 2007-01-15 Novartis Vaccines & Diagnostic Antagonistiske monoklonale antistoffer mod humant CD40
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
NZ273504A (en) 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding
ES2222463T3 (es) * 1993-12-23 2005-02-01 Immunex Corporation Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos.
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ATE363290T1 (de) * 1999-10-04 2007-06-15 Novartis Vaccines & Diagnostic Cd40 antagonist zur behandlung von psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
EP1322383B9 (en) 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies

Also Published As

Publication number Publication date
JP2004517611A (ja) 2004-06-17
WO2002028481A2 (en) 2002-04-11
AU2002211366A1 (en) 2002-04-15
WO2002028480A3 (en) 2002-07-11
WO2002028481A3 (en) 2003-03-06
US20090081242A1 (en) 2009-03-26
WO2002028904A2 (en) 2002-04-11
JP2009019046A (ja) 2009-01-29
CA2424296A1 (en) 2002-04-11
EP1717251A3 (en) 2007-11-07
AU2001296507A1 (en) 2002-04-15
JP4838831B2 (ja) 2011-12-14
JP2009201523A (ja) 2009-09-10
ATE541860T1 (de) 2012-02-15
WO2002028904A3 (en) 2003-02-06
US20100172912A1 (en) 2010-07-08
WO2002028905A2 (en) 2002-04-11
US7820170B2 (en) 2010-10-26
EP1717251A2 (en) 2006-11-02
DE60119945T2 (de) 2007-01-18
ES2357051T3 (es) 2011-04-15
US8088383B2 (en) 2012-01-03
US7288252B2 (en) 2007-10-30
US20110033456A1 (en) 2011-02-10
EP1322383B9 (en) 2006-09-06
JP2004510752A (ja) 2004-04-08
JP2008156339A (ja) 2008-07-10
ATE327004T1 (de) 2006-06-15
PT1326896E (pt) 2011-03-03
EP1326896A2 (en) 2003-07-16
JP2008074870A (ja) 2008-04-03
US7445780B2 (en) 2008-11-04
WO2002028480A2 (en) 2002-04-11
US20040109857A1 (en) 2004-06-10
EP1322383A2 (en) 2003-07-02
EP1322383B1 (en) 2006-05-24
EP1326896B1 (en) 2010-11-24
DE60143535D1 (de) 2011-01-05
DE60119945D1 (de) 2006-06-29
ATE489403T1 (de) 2010-12-15
WO2002028481A9 (en) 2003-07-03
AU2001296547A1 (en) 2002-04-15
US7611708B2 (en) 2009-11-03
JP4271440B2 (ja) 2009-06-03
JP4202127B2 (ja) 2008-12-24
EP1717251B1 (en) 2012-01-18
WO2002028905A3 (en) 2002-06-20
US20080075727A1 (en) 2008-03-27
CA2424749A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
AU2001296545A1 (en) Methods of therapy for b-cell malignancies
WO2005044304A3 (en) Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP1684805B8 (en) Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005044854A3 (en) Antagonist anti-cd40 monoclonal antibodies and methods for their use
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
EP1680141B8 (en) Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
WO2005044307A3 (en) Methods of therapy for b cell-related cancers
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
AU7031500A (en) Therapeutic quinazoline compounds
WO2000020864A8 (en) Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
NZ515464A (en) Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
AU3386100A (en) Anti-tnfalpha antibodies in therapy of asthma
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
WO2004019886A3 (en) Methods for up-regulating antigen expression in tumors
RU2002103808A (ru) Способ лечения болевого синдрома у онкологических больных
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
WO2004019991A3 (en) Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
WO2000010590A3 (en) Cancer treatment
AU4209097A (en) Breast carcinoma-associated gene
NZ329403A (en) Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L